5 Analysts Assess Century Therapeutics: What You Need To Know
Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety…
Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-Derived Cell Therapy Platform Technology At The 2024 AACR Annual Meeting
Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps & Tech-heavy QQQ ETF by 11.4% (MTD)
Recap: Century Therapeutics Q3 Earnings
Century Therapeutics (NASDAQ:IPSC) reported its Q3 earnings results on Thursday, November 9, 2023 at 07:00 AM. Here’s what…
Century Therapeutics To Present Initial Clinical Data Supporting The Potential For A Multi-Dosing Strategy For CAR iNK Enabled By Allo-Evasion Edits At The 65th ASH Annual Meeting And Exposition
– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support, and a safety switch – –
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 112 companies set new 52-week lows.
Benzinga’s Top Ratings Upgrades, Downgrades For August 28, 2023
Upgrades According to B of A Securities, the prior rating for Futu Holdings Ltd (NASDAQ:FUTU) was changed from…
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares gained 0.5% to close at $93.30 on Friday.